Core Insights - The expert consensus on the prevention and treatment of vascular diseases and their target organ damage has been officially released, with the core product of Wuzhou Pharmaceutical, an affiliate of Zhongheng Group, namely the injectable Thrombus-Resolving Agent (freeze-dried), being included as a recommended medication for "activating blood circulation and removing blood stasis" [1][2] - The injectable Thrombus-Resolving Agent received the highest level of evidence (Ia) and an A-level recommendation, establishing it as a significant choice in the field of traditional Chinese medicine for multi-target organ protection against vascular diseases [1] Industry and Company Summary - The expert consensus was guided by academicians Ge Junbo and Chen Keji, involving 43 authoritative experts from 19 provinces, covering key areas of vascular diseases such as cardiovascular, cerebrovascular, renal, ocular, peripheral vascular, and endocrine [1] - The injectable Thrombus-Resolving Agent's clinical value is highlighted by its indications, which include coronary heart disease angina, myocardial infarction, cerebral infarction, retinal vein occlusion, and deep vein thrombosis of the lower limbs, addressing the treatment needs of multiple target organs [1][2] - The inclusion of the injectable Thrombus-Resolving Agent in the expert consensus not only recognizes its clinical efficacy but also marks a significant step in Wuzhou Pharmaceutical's academic positioning in the field of vascular disease treatment, reinforcing its industry status in traditional Chinese medicine [2]

Core Viewpoint - The article highlights the increasing risk of cardiovascular diseases (CVD) during the autumn and winter seasons, particularly among vulnerable populations such as the elderly and those with pre-existing health conditions. It emphasizes the importance of awareness regarding early symptoms and preventive measures to mitigate risks associated with cold weather and lifestyle factors. Group 1: Cardiovascular Disease Statistics - In 2021, CVD was the leading cause of death among urban and rural residents in China, accounting for 48.98% and 47.35% of deaths respectively [3] - The crude incidence rate of CVD among residents aged 18 and above in 2023 was 620.33 per 100,000, with males at 717.36 and females at 519.64, showing a significant increase with age [3] Group 2: Seasonal Impact on Cardiovascular Health - Cold weather poses a direct challenge to blood vessels, leading to constriction and increased blood pressure, which heightens the heart's workload [4] - The autumn and winter seasons coincide with a rise in respiratory infections, which can indirectly harm the cardiovascular system and increase the risk of acute myocardial infarction [6] Group 3: High-Risk Populations - Elderly individuals and young professionals under high stress are identified as high-risk groups for cardiovascular events during the colder months [6][9] - Lifestyle factors such as obesity, hypertension, and sedentary behavior contribute to the increasing prevalence of CVD among younger populations [9] Group 4: Early Symptoms and Misdiagnosis - Common early symptoms of cardiovascular issues include fatigue, chest discomfort, palpitations, and sleep disturbances, which are often overlooked or misdiagnosed as gastrointestinal problems [7] - Patients frequently visit other medical departments without receiving appropriate cardiovascular care, highlighting the need for better awareness and education [8] Group 5: Preventive Measures and Lifestyle Recommendations - Maintaining a healthy lifestyle, including a balanced diet low in salt and high in fruits and vegetables, is crucial for preventing cardiovascular diseases [10] - Regular physical activity, stress management, and adequate sleep are essential components of cardiovascular health [11] - During cold weather, individuals are advised to dress warmly and engage in moderate exercise to adapt to temperature changes [11]